Nurse Practitioner Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Rita Norelli

Registered Nurse Arvada, CO Nurse Practitioner

NPI 1679227821 CMS profile 11367096

8850 Ralston Rd Ste 102, Arvada, CO 80002

Open in the dashboard

General payments

$3,667

200 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rita Norelli of Arvada, CO is reported in the CMS Open Payments database as having received $3,667 across 200 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Registered Nurse profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $998 60
2024 General $1,454 72
2023 General $1,215 68

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rita Norelli
  • Registered Nurse median
  • Middle half of Registered Nurse
  • National median

In program year 2025, general payments to Rita Norelli were reported at $998. Among 1,661 Registered Nurse profiles paid that year, the median was $74 and the middle half received between $27 and $193.

Show as a table
Year Rita Norelli Registered Nurse median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $53 $20–$148 $132
2022 $0 $53 $21–$146 $149
2023 $1,215 $84 $26–$196 $160
2024 $1,454 $80 $26–$187 $164
2025 $998 $74 $27–$193 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. AbbVie, Inc. $943 40 payments
  2. Pfizer Inc. $676 33 payments
  3. GlaxoSmithKline, LLC. $364 19 payments
  4. Amgen Inc. $304 26 payments
  5. AstraZeneca Pharmaceuticals LP $264 11 payments
  6. Lilly USA, LLC $229 26 payments
  7. Exact Sciences Corporation $186 8 payments
  8. Otsuka America Pharmaceutical, Inc. $127 6 payments
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $98 7 payments
  10. Novo Nordisk Inc $89 5 payments
  11. Other $388 19 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $3,667 200 payments
Products named General payments · program years 2023–2025
  1. NURTEC ODT $572 28 payments
  2. ZAVZPRET $525 26 payments
  3. UBRELVY $399 16 payments
  4. VRAYLAR $387 16 payments
  5. Otezla $246 22 payments
  6. MOUNJARO $187 23 payments
  7. COMIRNATY $177 8 payments
  8. QULIPTA $175 10 payments
  9. SHINGRIX $166 8 payments
  10. Cologuard Collection Kit $162 7 payments
  11. Other $2,522 136 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

584

Median for Registered Nurse: 109

Drug cost

$5,298

Median for Registered Nurse: $4,454

Branded share of claims

19.5%

Median for Registered Nurse: 15.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Synthroid Levothyroxine Sodium Brand 11 $1,159
Allopurinol Generic 20 $368
Atorvastatin Calcium Generic 53 $325
Albuterol Sulfate Hfa Albuterol Sulfate Brand 14 $305
Bupropion Xl Bupropion Hcl Brand 12 $281
Levothyroxine Sodium Generic 44 $256
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 27 $252
Simvastatin Generic 31 $245
Rosuvastatin Calcium Generic 31 $237
Omeprazole Generic 23 $218

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 476 Part D prescribers listed as Registered Nurse; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $213
$213 — —
UBRELVY
  • AbbVie, Inc. $161
$161 — —
ZAVZPRET
  • PFIZER INC. $146
$146 — —
NURTEC ODT
  • PFIZER INC. $134
$134 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $77
$77 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

200 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record